Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer

Drugs of Today

Volumn 51, Issue 1, 2015, Pages 7-20

  McDermott, J ^a   Jimeno, A ^a,b  

^a Division of Medical Oncology   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anti PD 1 antibody; Lambrolizumab; Melanoma; MK 3475; NSCLC; Pembrolizumab

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; DEXAMETHASONE; DOCETAXEL; IMMUNOGLOBULIN G4; IPILIMUMAB; LENALIDOMIDE; PAZOPANIB; PEGINTERFERON; PEMBROLIZUMAB; POMALIDOMIDE; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ABSCESS; ACNE; ADVANCED CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL TUMOR; DECREASED APPETITE; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ATRIUM FIBRILLATION; HODGKIN DISEASE; HUMAN; HYPONATREMIA; HYPOTHYROIDISM; IMMUNE EVASION; IMMUNE RESPONSE; INFUSION RELATED REACTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LIVER FAILURE; LYMPHOCYTE; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; MYALGIA; MYCOSIS FUNGOIDES; NEPHRITIS; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERICARDIAL EFFUSION; PNEUMONIA; PRURITUS; RASH; SARCOMA; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84922339585     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.1.2250387     Document Type: Article

References (68)

1. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-64.
2. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-74.
3. Ehrlich, R. Ueber den jetzigen stand der karzinomforshung. Ned Tijdschr Geneeskd 1909, 5:73-290.
4. Burnet, M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957, 1(5023):841-7.
5. Zou, W., Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8(6):467-77.
6. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(4):295-307.
7. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4(5):336-47.
8. Sharpe, A. H., Freeman, G. J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2(2):116-26.
9. Korman, A. J., Peggs, K. S., Allison, J. P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
10. Krummel, M. F., Allison, J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting Tcells. J Exp Med 1996, 183(6):2533-40.
11. Walunas, T. L., Bakker, C. Y., Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996, 183(6):2541-50.
12. Leach, D. R., Krummel, M. F., Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-6.
13. Peggs, K. S., Quezada, S. A., Allison, J. P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224:141-65.
14. Hodi, F. S., O'Day, S. J., McDermott, D. F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-23.
15. Robert, C., Thomas, L, Bondarenko, I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-26.
16. Kirkwood, J. M., Lorigan, P., Hersey, P. et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16(3):1042-8.
17. Ribas, A., Kefford, R., Marshall, M. A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31(5):616-22.
18. Zhang, X., Schwartz, J. C., Guo, X. et al. Structural and functional analysis of the costimulatory receptor programmed death-l. Immunity 2004, 20(3):337-47.
19. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
20. Greenwald, R. J., Freeman, G. J., Sharpe, A. H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-48.
21. Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., Leonard, J. P. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002, 9(2):133-45.
22. Latchman, Y., Wood, C. R., Chernova, T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2(3):261-8.
23. Parry, R. V., Chemnitz, J. M., Frauwirth, K. A. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25(21):9543-53.
24. Saunders, P. A., Hendrycks, V. R., Lidinsky, W. A., Woods, M. L. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. EurJ Immunol 2005, 35(12):3561-9.
25. Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., Sharpe, A. H. PD-L1 regulates the development, maintenance, and function of induced regulatory Tcells. J Exp Med 2009, 206(13):3015-29.
26. Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., Drake, C. G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69(15):1694-703.
27. Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., Rosenberg, S. A. Tumor antigen-specific CDS T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114(8):1537-44.
28. Dong, H., Strome, S. E., Salomao, D. R. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
29. Thompson, R. H., Gillett, M. D., Cheville, J. C. et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004, 101(49):17174-9.
30. Dorfman, D. M., Brown, J. A., Shahsafaei, A., Freeman, G. J. Programmed death-1 (PD-1) is a marker of germinal centerassociated Tcells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006, 30(7):802-10.
31. Liu, J., Hamrouni, A., Wolowiec, D. et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110(1):296-304.
32. Kuang, D. M., Zhao, Q., Peng, C., Xu, J., Zhang, J. P, Wu, C., Zheng, L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009, 206(6):1327-37.
33. Hamanishi, J., Mandai, M., Iwasaki, M. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104(9):3360-5.
34. Inman, B. A., Sebo, T. J., Frigola, X. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007, 109(8):1499-505.
35. Ohigashi, Y., Sho, M., Yamada, Y. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11(8):2947-53.
36. Nomi, T., Sho, M., Akahori, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7):2151-7.
37. Parsa, A. T., Waldron, J. S., Panner, A. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13(1):84-8.
38. Marzec, M., Zhang, Q., Goradia, A. et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008, 105(52):20852-7.
39. Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., Gajewski, T. F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCP) transgenic CD8+ Tcells. Cancer Res 2004, 64(3):1140-5.
40. Iwai, Y., Ishicla, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99(19):12293-7.
41. Strome, S. E., Dong, H., Tamura, H. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63(19):6501-5.
42. Iwai, Y., Terawaki, S., Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005, 17(2):133-44.
43. Okazaki, T., Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19(7):813-24.
44. Patnaik, A., Kang, S. P., Tolcher, A. W., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 2512.
45. Hamid, O., Robert, C., Daud, A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2):134-44.
46. Sriram, V., Bigler, M. E., Cherwinski, H., Murphy, E., McClanahan, T. K., Phillips, J. H. Dissecting the dynamics of anti-PDl immunotherapy in predinical tumor models. Cancer Res [105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014] 2014, 74: Abst 5025.
47. Darr, D., Clark, K. S., Phillips, J. H., et al. mDX400, the murine analog against the anti-PDl antibody MK-3475 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer. Cancer Res [105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014] 2014, 74: Abst 5024.
48. Merck & Co. KEYTRUDA (pembrolizumab) Prescribing Information. 2014. http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf. Accessed October, 2014.
49. Robert, C., Ribas, A., Wolchok, J. D. et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-17.
50. Wolchok, J. D., Hoos, A., O'Day, S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-20.
51. Kefford, R., Ribas, A., Hamid, O., et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients with melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago)] 2014, 32(5s, suppl.): Abst 3005.
52. Bagcchi, S. Pembrolizumab for treatment of refractory melanoma. Lancet Oncol 2014, 15(10):e419.
53. Hamid, O., Robert, C., Ribas, A., et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and ipilimumab-nai've (IPI-N) melanoma. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014, 32(5s, suppl): Abst 3000.
54. Ribas, A., Hodi, F. S., Kefford, R., et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK2475 in 411 patients with melanoma. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst LBA9000.
55. Hodi, F. S., Ribas, A., Daud, A., et al. Evaluation of immunerelated response criteria (irRC) in patients with advanced melanoma treated with the anti-PD-1 monoclonal antibody MK3475. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst 3006.
56. Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst 3015.
57. Daud, A., Hamid, O., Ribas, A., et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: Correlation of tumor PD-L1 expression with outcome. Cancer Res [105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014] 2014, 74: Abst CT104.
58. Garon, E. B., Leighl, N. B., Rizvi, N. A., et al. Safety and clinical activity of MK-3475 in previously treated patients with non-small cell lung cancer. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst 8020.
59. Gandhi, L., Balmanoukian, A., Hui, R., et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression. Cancer Res [105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014] 2014, 74: Abst CT105.
60. Rizvi, N. A., Garon, E. B., Patnaik, A., et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst 8007.
61. Seiwert, T. Y., Burtness, B., Weiss, J., et al. A phase lb study of MK-3475 in patients with HPV-associated and non-HPV associated head and neck cancer. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s, suppl.): Abst 6011.
62. ClinicalTrials.gov Web site, http://clinicaltrials.gov/ct2/results?term=mk-3475&Search=Search. Accessed December 21, 2014.
63. Austin, C. J., Rendina, L. M. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today 2014: Advanced publication.
64. Shih, K., Arkenau, H. T., Infante, J. R. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014, 74(17):1993-2013.
65. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-54.
66. Berger, R., Rotem-Yehudar, R., Slama, G.etal. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14(10):3044-51.
67. Selby, M., Engelhardt, J., Lu, L.-S., et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013] 2013, 31(Suppl.): Abst 3061.
68. Wolchok, J. D., Kluger, H., Callahan, M. K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-33.